
Sign up to save your podcasts
Or


Peter Kolchinsky, RA Capital's founder and managing partner, joins to talk about why so many of the policy ideas floated around drug-pricing are wrongheaded. Industry is going to have to give "a pound of flesh," Kolchinsky argued, and he's explicit on the business practices biopharma must abandon to get a fair system that still rewards innovation.
Peter literally wrote the book on the topic -- the Great American Drug Deal -- and it's well worth having on your bookshelf.
By W2O GroupPeter Kolchinsky, RA Capital's founder and managing partner, joins to talk about why so many of the policy ideas floated around drug-pricing are wrongheaded. Industry is going to have to give "a pound of flesh," Kolchinsky argued, and he's explicit on the business practices biopharma must abandon to get a fair system that still rewards innovation.
Peter literally wrote the book on the topic -- the Great American Drug Deal -- and it's well worth having on your bookshelf.